Literature DB >> 32454688

A Validated Reverse Phase-Ultra-Performance Liquid Chromatography Method for the Determination of Gemifloxacin Mesylate in Bulk and its Pharmaceutical Preparation.

Hebatallah A Wagdy1,2, Mohamed Tarek1,2, Ahmed Amer2, Menna Gamal2, Mohey Elmazar2,3.   

Abstract

OBJECTIVES: Gemifloxacin Mesylate is a fourth generation fluoroquinolone antibacterial agent. A simple, accurate, and precise reversed phase (RP)-ultra performance liquid chromatography (UPLC) method was developed and validated for short time analysis of Gemifloxacin Mesylate in its bulk and pharmaceutical preparation.
MATERIALS AND METHODS: The optimum separation was achieved at 0.5±0.03 min using an AcclaimTM RSLC 120 C18 column 2.2 μm (2.1×100 mm) at 30°C by isocratic mobile phase at pH 3.0 composed of acetonitrile:phosphate buffer (25 mM) in a ratio of 75:25 (v/v). The column effluents were monitored at 276 nm using a photodiode array detector at a flow rate of 0.5 mL/min. The method was validated according to International Conference on Harmonization guidelines.
RESULTS: The linearity of the calibration curve ranged from 0.5 μg/mL to 10 μg/mL and the square of the regression coefficient (r2) was 0.9991. The % relative standard deviation (RSD) of inter-day precision ranged from 0.081% to 1.233%, while for intra-day it ranged from 0.364% to 1.018%. The method was accurate with % recovery ranging from 93.71% to 100.29% and % RSD ranging from 1.054 to 2.722. The limit of detection and the limit of quantification were 0.066 and 0.2 μg/mL, respectively.
CONCLUSION: The validated method proved its ability for the assay of Gemifloxacin Mesylate in its bulk and dosage form in a short time (less than 1 min). To the best of our knowledge, this is the first RP-UPLC method for the determination of Gemifloxacin Mesylate. ©Copyright 2019 Turk J Pharm Sci, Published by Galenos Publishing House.

Entities:  

Keywords:  Gemifloxacin Mesylate; method validation; ultra performance liquid chromatography

Year:  2018        PMID: 32454688      PMCID: PMC7227989          DOI: 10.4274/tjps.04934

Source DB:  PubMed          Journal:  Turk J Pharm Sci        ISSN: 1304-530X


  9 in total

1.  International multicenter investigation of LB20304, a new fluoronaphthyridone.

Authors:  Annik F. Hohl; Reno Frei; Verena Pünter; Alexander von Graevenitz; Cynthia Knapp; John Washington; David Johnson; Ronald N. Jones
Journal:  Clin Microbiol Infect       Date:  1998-05       Impact factor: 8.067

2.  In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.

Authors:  J I Oh; K S Paek; M J Ahn; M Y Kim; C Y Hong; I C Kim; J H Kwak
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

3.  Spectrofluorimetric determination of gemifloxacin mesylate and linezolid in pharmaceutical formulations: Application of quinone-based fluorophores and enhanced native fluorescence.

Authors:  Bahia Abbas Moussa; Marianne Alphonse Mahrouse; Mahmoud Ali Hassan; Michael Gamal Fawzy
Journal:  Acta Pharm       Date:  2014-03       Impact factor: 2.230

4.  Highly selective colorimetric method to determine gemifloxacin mesylate in the presence of a synthetic impurity.

Authors:  Clésio S Paim; Fernanda Führ; Diogo S Miron; Martin Steppe; Elfrides E S Schapoval
Journal:  J AOAC Int       Date:  2014 Jan-Feb       Impact factor: 1.913

5.  Spectrofluorimetric methods for the determination of gemifloxacin in tablets and spiked plasma samples.

Authors:  Serife Evrim Kepekci Tekkeli; Armağan Önal
Journal:  J Fluoresc       Date:  2010-10-28       Impact factor: 2.217

6.  Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone.

Authors:  M G Cormican; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

7.  Reverse phase-HPLC and HPTLC methods for determination of gemifloxacin mesylate in human plasma.

Authors:  A R Rote; S P Pingle
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-08-18       Impact factor: 3.205

8.  Determination of gemifloxacin in different tissues of rat after oral dosing of gemifloxacin mesylate by LC-MS/MS and its application in drug tissue distribution study.

Authors:  Bikash Roy; Ayan Das; Uttam Bhaumik; Amlan Kanti Sarkar; Anirbandeep Bose; Jayanti Mukharjee; Uday Sankar Chakrabarty; Anjan Kumar Das; Tapan Kumar Pal
Journal:  J Pharm Biomed Anal       Date:  2009-12-29       Impact factor: 3.935

9.  HPTLC method for direct determination of gemifloxacin mesylate in human plasma.

Authors:  W M El-Koussi; N N Atia; A M Mahmoud; S R El-Shabouri
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2014-07-11       Impact factor: 3.205

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.